Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1  ≥ 50 % progressing on first-line pembrolizumab

Approximately 100 people die of lung cancer in the UK each day [1]. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, accounting for 85  % of all cases. In Scotland approximately 45 % of patients diagnosed with NSCLC have stage IV disease [2]. Pembrolizumab is an established first-line treatment option for patients with advanced NSCLC expressing PD-L1 ≥ 50 %. Such high PD-L1 expression is observed in approximately 25 % of patients with advanced NSCLC screened in clinical trials [3,4].

Source: Lung Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Mark Stares, Emma Doyle, Sally Chapple, George Raynes, James MacDonald, Colin Barrie, Barry Laird, Melanie MacKean, Iain Philips Source Type: research